A phase 2 trial of another MUC1 vaccine is currently underway to evaluate its ability to decrease recurrence rates in patients with a history of advanced adenoma (those with high-grade dysplasia, villous/tubulovillous features, or tumors larger than 1 cm) [47]. The gene discussed is MUC1; the disease is adenoma.